Investigative bimekizumab shows significant efficacy in plaque psoriasis
Article written by Bruce Sylvester Researchers report that patients treated with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, have achieved significant… read more.